Edition:
United States

Heat Biologics Inc (HTBX.OQ)

HTBX.OQ on NASDAQ Stock Exchange Capital Market

1.13USD
4:00pm EDT
Change (% chg)

$0.01 (+0.89%)
Prev Close
$1.12
Open
$1.14
Day's High
$1.22
Day's Low
$1.13
Volume
6,009
Avg. Vol
52,393
52-wk High
$7.96
52-wk Low
$1.09

Select another date:

Fri, Mar 30 2018

BRIEF-Heat Biologics Files For Offering Of Up To $15 Mln Of Its Common Stock

* FILES FOR OFFERING OF UP TO $15 MILLION OF ITS COMMON STOCK - SEC FILING Source text for Eikon: (http://bit.ly/2GFwyfW) Further company coverage:

BRIEF-Heat Biologics Reports Data From Phase 2 Trial Of HS-410 Combined With Bacillus Calmette-Guérin For Treating Non-Muscle Invasive Bladder Cancer

* HEAT BIOLOGICS - REPORTS 2 YEAR DATA FROM PHASE 2 TRIAL OF HS-410 COMBINED WITH BACILLUS CALMETTE-GUÉRIN FOR TREATING NON-MUSCLE INVASIVE BLADDER CANCER

BRIEF-Heat Biologics Files Prospectus Supplement Related To Offering Of Up To $1.3 Million Shares Of Co's Common Stock

* HEAT BIOLOGICS INC FILES PROSPECTUS SUPPLEMENT RELATED TO OFFERING OF UP TO $1.3 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING‍​ Source text (http://bit.ly/2G2V1vx) Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Heat Biologics - Interim Results From Phase 2 Study Investigating HS-110 In Combination With Anti-PD-1

* HEAT BIOLOGICS - INTERIM RESULTS FROM PHASE 2 STUDY INVESTIGATING HS-110 IN COMBINATION WITH BRISTOL-MYERS'S ANTI-PD-1 CHECKPOINT INHIBITOR, NIVOLUMAB

BRIEF-Heat Biologics Gets Recommendation To Continue Patient Enrollment Of Ongoing Phase 2 Clinical Trial

* SAYS GOT INDEPENDENT DMC RECOMMENDATION TO CONTINUE PATIENT ENROLLMENT OF ONGOING PHASE 2 CLINICAL TRIAL FOR HS-110 AND NIVOLUMAB​ Source text: (http://bit.ly/2BG2kXt) Further company coverage:

BRIEF-Heat Biologics Says Receives FDA Guidance At Type C Meeting For HS-110 Clinical Trial

* SAYS RECEIVES FDA GUIDANCE AT TYPE C MEETING FOR HS-110 CLINICAL TRIAL

BRIEF-Heat Biologics reports Q3 net loss attributable to Heat $0.06 per basic and diluted share‍​

* Heat Biologics Inc - qtrly net loss attributable to Heat for the third quarter of 2017 was $0.06 per basic and diluted share‍​

BRIEF-Heat Biologics Inc files for mixed shelf of up to $50 million ‍​

* Heat Biologics Inc files for mixed shelf of up to $50 million – SEC filing ‍​ Source text - (http://bit.ly/2ltFdsE) Further company coverage:

Select another date: